Aclaris Therapeutics (ACRS) Treasury Shares (2014 - 2026)

Aclaris Therapeutics' Treasury Shares history runs 9 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, Treasury Shares fell 41.66% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 41.66% decrease from a year earlier, with the FY2025 full-year figure at $2.2 million, up 3.99% from the prior year.
• Treasury Shares declined to $1.9 million in Q1 2026 per ACRS's latest filing, from $2.2 million in the prior quarter.
• Across five years, Treasury Shares topped out at $3.2 million in Q1 2025 and bottomed at $2375.0 in Q2 2022.
• The 5-year median for Treasury Shares is $1.7 million (2023), against an average of $1.7 million.
• Across the five-year window, Treasury Shares slumped 99.84% in 2022 and surged 72322.74% in 2023, its largest moves.
• Year by year, Treasury Shares stood at $1.5 million in 2022, then grew by 0.08% to $1.5 million in 2023, then plunged by 88.17% to $180000.0 in 2024, then surged by 1111.05% to $2.2 million in 2025, then decreased by 15.04% to $1.9 million in 2026.
• Per Business Quant, the three latest ACRS Treasury Shares figures stand at $1.9 million (Q1 2026), $2.2 million (Q4 2025), and $241840.0 (Q3 2025).